|Articles|June 1, 2008

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2008
  • Volume 0
  • Issue 0

Wendy Niebler, Shire

S

Wendy Niebler

Vice President, Global Medical Affairs, ADHD, Shire

EDUCATION: DO from Ohio University College ofOsteopathic Medicine, MBA from St. Joseph's University

ACCOMPLISHMENT: Designed Cephalon's largest global clinical program in under two years

On joining the pharma industry:

I started out as a physician in private practice. But the scientific aspect of clinical trial work motivated me to join Cephalon, because I had a chance to not only run, but design, clinical trials. It was an opportunity of a lifetime. As a physician going to industry, you can miss that day-to-day contact with patients. But it's reassuring to know you can impact patients even in a wider sense.

Wendy Niebler

Articles in this issue

over 18 years ago

Mary Szela, Abbott

over 18 years ago

Mightier Than the Sword

over 18 years ago

Eric Floyd, Cephalon

over 18 years ago

Nancy Phelan, Wyeth

over 18 years ago

Tightening the Chain

over 18 years ago

Kurt Graves, Vertex

over 18 years ago

Perfectly Imperfect

over 18 years ago

Relaunching Reform

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.